We are live on ! Find out more

KLRA

Kailera Therapeutics

KLRA

Market cap $1.66B

12.83 USD

-0.09

0.7%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

13.00

+0.17

1.33%

1 day

-0.7%

5 days

-7.76%

1 month

-28.04%

3 months

-35.53%

6 months

-50.65%

Year to date

-50.65%

1 year

-50.65%

5 years

-50.65%

10 years

-50.65%

About: Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 44.4%

Neutral 44.4%

Negative 11.1%

Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval

Kailera Therapeutics, Inc. targets the high-potential GLP-1 obesity market, leveraging a $718M IPO and a robust pipeline licensed from Hengrui. KLRA's lead candidate, ribupatide, shows competitive mean weight loss (23.6% at 36 weeks) and a favorable safety profile in ex-China studies. Despite a 40% post-IPO share price drop, KLRA's $1.65 bn valuation appears attractive given its late-stage pipeline and $900m cash balance.

Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval

Kailera Therapeutics to Participate in September Investor Conferences

WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced participation in the following investor conferences: Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Wednesday, September 23, 2026, 9:40 a.m.

Kailera Therapeutics to Participate in September Investor Conferences

24/7 Wall Street

Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore

Kailera Therapeutics (NASDAQ:KLRA) closed most recently at $18.51, between a post-IPO high of $28.23 and low of $16.39, with a $2.40 billion market cap.

Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027 Expanded executive team to strengthen technical operations capabilities and corporate affairs leadership Cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028 WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the second quarter ended June 30, 2026, and provided a summary of recent business highlights.

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win

Kailera is building a multi-modal obesity franchise with exclusive global rights to Hengrui Pharma's obesity portfolio, leveraging late-stage assets and ongoing data. KLRA's robust cash position—over $1.3 billion post-IPO—funds operations through mid-2028, supporting multiple pivotal trial readouts before further capital is needed. Pipeline catalysts include global Phase 3 trials for ribupatide and promising Phase 2/3 data for oral GLP-1 candidates, targeting differentiated efficacy and convenience.

Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win

Why Is Kailera Therapeutics Stock Falling Tuesday?

Kailera Therapeutics Inc. (NASDAQ:KLRA) stock fell about 9% on Tuesday after the company reported positive topline results from two Phase 3 trials of its oral GLP-1 drug candidate HRS-7535/KAI-7535 in China.

Why Is Kailera Therapeutics Stock Falling Tuesday?

Kailera's GLP-1 drug meets main goal of late-stage trials

Kailera Therapeutics said ‌on Tuesday its GLP-1 ⁠drug for patients with diabetes and obesity met the ‌main ⁠goal of two-late stage ⁠trials.

Kailera's GLP-1 drug meets main goal of late-stage trials

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Ka

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

Biotech ETF Index Surges 10% After Rebalance

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.

Biotech ETF Index Surges 10% After Rebalance

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with v omiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively Phase 1 single ascending dose trial, the first ribupatide injection clinical data generated outside of China, demonstrated similar exposure, tolerability, and weight reduction in participants of Asian and non-Asian descent SHANGHAI and WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced clinical results for ribupatide (also known as HRS9531 or KAI-9531), a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight, presented at the 86th Scientific Sessions of the American Diabetes Association (ADA).

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

See News Rankings

Price charts implemented using Lightweight Charts™